MetaVia Inc. (MTVA)
MTVA moved a median of -0.87% 30 minutes after news, and +0.63% by the close. How MTVA actually reacts to news — the realized, point-in-time move the market made, measured across 128 labeled events over the last three years with zero look-ahead.
MTVA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 125 |
| 30-min | -0.87% | 37% | 128 |
| 60-min | -0.41% | 45% | 128 |
| to close | +0.63% | 54% | 128 |
| Middle 50% of MTVA reactions | -4.40% to +1.09% |
|---|---|
| Median reaction (30-min) | -0.87% |
| Measured reactions | 128 |
Half of all MetaVia Inc. news events land between -4.40% and +1.09% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MTVA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MTVA's baseline. Nothing else.
Recent MTVA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K MetaVia Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -1.65% | -5.92% | |
| MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer | Press release | PR Newswire | -1.65% | -5.92% | |
| Form 8-K MetaVia Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -6.89% | +2.35% | |
| MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction | Press release | PR Newswire | -6.89% | +2.35% | |
| Form 10-Q MetaVia Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.11% | +4.20% | |
| Form 8-K MetaVia Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.11% | +4.20% | |
| MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +3.11% | +4.20% | |
| Form 8-K MetaVia Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +8.80% | |
| MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity | Press release | PR Newswire | +0.63% | +8.80% | |
| Form 8-K MetaVia Inc. For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | +2.13% | +7.09% | |
| Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing | Press release | GlobeNewswire | +1.33% | -4.67% | |
| Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th | Press release | GlobeNewswire | +3.33% | +2.67% | |
| MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum | Press release | PR Newswire | -1.25% | +6.88% | |
| Form 8-K MetaVia Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -2.26% | +0.45% | |
| Form S-8 MetaVia Inc. | SEC filing · Form S-8 | SEC EDGAR | -4.95% | +3.85% | |
| MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential | Press release | PR Newswire | -2.26% | +0.45% | |
| MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference | Press release | PR Newswire | -1.13% | -7.55% | |
| Form 8-K MetaVia Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +22.61% | +21.90% | |
| MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH | Press release | PR Newswire | +22.61% | +21.90% | |
| MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH | Press release | PR Newswire | -2.02% | +45.96% | |
| Form 8-K MetaVia Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | +0.91% | |
| MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions | Press release | PR Newswire | +0.46% | +0.91% | |
| Form 10-Q MetaVia Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.71% | -5.13% | |
| Form 8-K MetaVia Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | -5.13% | |
| MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +1.71% | -5.13% | |
| Form 8-K MetaVia Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -7.56% | -12.61% | |
| MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 | Press release | PR Newswire | -7.56% | -12.61% | |
| Form ARS MetaVia Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.94% | +0.63% | |
| Form DEF 14A MetaVia Inc. For: Jun 08 | SEC filing · Form DEF | SEC EDGAR | -0.94% | +0.63% | |
| Form PRE 14A MetaVia Inc. For: Jun 08 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.72% | |
| Form 8-K MetaVia Inc. For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +15.57% | |
| MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity | Press release | PR Newswire | +0.41% | +15.57% | |
| Form EFFECT MetaVia Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.83% | |
| Form POS AM MetaVia Inc. | SEC filing · Form POS | SEC EDGAR | +3.15% | -3.94% | |
| Form S-8 MetaVia Inc. | SEC filing · Form S-8 | SEC EDGAR | +3.15% | -3.94% | |
| Form 10-K MetaVia Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.45% | +1.54% | |
| Form 8-K MetaVia Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +2.45% | +1.54% | |
| MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +2.45% | +1.54% | |
| Form 8-K MetaVia Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -3.11% | -8.07% | |
| MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control | Press release | PR Newswire | -3.11% | -8.07% | |
| MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 | Press release | PR Newswire | -1.23% | -1.23% | |
| MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum | Press release | PR Newswire | +0.00% | +1.26% | |
| MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference | Press release | PR Newswire | -4.27% | -6.10% | |
| MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 | Press release | PR Newswire | -1.64% | -10.38% | |
| MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel | Press release | PR Newswire | +2.38% | -1.59% | |
| Form 8-K MetaVia Inc. For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +1.92% | -10.00% | |
| Form 8-K MetaVia Inc. For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | -3.23% | |
| Form EFFECT MetaVia Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.89% | -6.89% | |
| MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option | Press release | PR Newswire | -0.65% | -3.23% | |
| Form S-1MEF MetaVia Inc. | SEC filing · Form S-1MEF | SEC EDGAR | -15.35% | -23.26% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MTVA section they belong to.
Where else MTVA is measured.
MTVA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MetaVia Inc.'s median reaction calculated?
Every labeled MTVA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 128 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of MTVA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MTVA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.